Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets

Cell-specific GEMs. Genome-scale metabolic models (GEMs) presenting the metabolism of drug-sensitive MCF7, doxorubicin-resistant MCF7 (MCF7/DXR), and paclitaxel-resistant MCF7 (MCF7/PR). Dataset S1. Metabolome profiles and analysis of MCF7, doxorubicin-resistant MCF7 (MCF7/DXR), and paclitaxel-resistant MCF7 (MCF7/PR). Dataset S2. Results of the joint pathway analysis using proteome and metabolome data from MCF7 and anticancer drug-resistant MCF7s (MCF7/DXR and MCF7/PR). Dataset S3. Metabolome profiles of doxorubicin-resistant MCF7 (MCF7/DXR) with and without V-9302 treatment. V-9302 is an inhibitor of SLC1A5.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-12-02
DOI
https://doi.org/10.5281/zenodo.13901565
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets

Zenodo (CERN European Organization for Nuclear Research)
Cancer, Hypoxia, and Metabolism
article

Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets

article en

Abstract

Cell-specific GEMs. Genome-scale metabolic models (GEMs) presenting the metabolism of drug-sensitive MCF7, doxorubicin-resistant MCF7 (MCF7/DXR), and paclitaxel-resistant MCF7 (MCF7/PR). Dataset S1. Metabolome profiles and analysis of MCF7, doxorubicin-resistant MCF7 (MCF7/DXR), and paclitaxel-resistant MCF7 (MCF7/PR). Dataset S2. Results of the joint pathway analysis using proteome and metabolome data from MCF7 and anticancer drug-resistant MCF7s (MCF7/DXR and MCF7/PR). Dataset S3. Metabolome profiles of doxorubicin-resistant MCF7 (MCF7/DXR) with and without V-9302 treatment. V-9302 is an inhibitor of SLC1A5.

Zenodo (CERN European Organization for Nuclear Research)
Seoul National University (KR), Korea Advanced Institute of Science and Technology (KR), Seoul National University Hospital (KR)
Good health and well-being
Openalex Percentile: Top 61%
Cancer, Hypoxia, and Metabolism
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets · Zenodo (CERN European Organization for Nuclear Research) (2024) | TGRS Research Map | TGRS